GlassScriptPhysician profile
Gustavo Carbone
NPI 1114116720
$14,752.79
in general payments reported to CMS, 2019-2025
33 companies · $4,017 in 2025
The $4,017 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $166 · 2021: $643 · 2022: $2,772 · 2023: $2,945 · 2024: $3,932 · 2025: $4,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,722.76 |
| Education | $171.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,007.22 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Abbvie INC. | $2,349.85 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,784.77 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $951.10 | 2021-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $827.80 | 2021-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $826.22 | 2021-2025 | |
| Glaxosmithkline, LLC. | $805.50 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $757.41 | 2022-2024 | Saphnelo, Evusheld |
| Genzyme Corporation | $483.23 | 2022-2025 | |
| Horizon Therapeutics Plc | $440.97 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $434.39 | 2022-2025 | Acthar |
| Genentech USA, INC. | $311.69 | 2021-2025 | Actemra |
| Pfizer INC. | $284.41 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $254.18 | 2023-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $208.68 | 2021-2025 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $179.41 | 2024-2025 | Orencia |
| Radius Health, INC. | $154.21 | 2019-2025 | Tymlos |
| Octapharma USA, INC. | $110.09 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Alexion Pharmaceuticals, INC. | $89.15 | 2022-2024 | Strensiq, Ultomiris |
| Scilex Pharmaceuticals INC. | $77.66 | 2024 | |
| Organon LLC | $74.89 | 2023-2025 | Hadlima, Renflexis |
| Sandoz INC. | $49.78 | 2023-2024 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $45.66 | 2024 | Opsumit, Uptravi |
| Fresenius Kabi USA, LLC | $35.06 | 2025 | Tyenne |
| Tonix Medicines, INC. | $31.96 | 2025 | Tonmya |
| Kyowa Kirin, INC. | $29.37 | 2024 | Crysvita |
| Tersera Therapeutics LLC | $24.30 | 2025 | Quzyttir |
| Mylan Institutional INC. | $23.89 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.57 | 2021 | |
| Grifols USA, LLC | $22.58 | 2023 | Xembify |
| Hospira, INC. | $22.55 | 2022 | |
| Bioventus LLC | $15.75 | 2023 | Durolane |
| Teva Pharmaceuticals USA, INC. | $15.49 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Carbone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.